A CSF-1R Ig4-5 Domain-Targeting Antibody for the Treatment of Idiopathic Pulmonary Fibrosis
Antibodies · 11.08.2026 · 15 (4) · 76
DOI: 10.3390/antib15040076 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibodies, online erschienen am 11.08.2026. Verfasst von Wusong Luo und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Genetics and Development of Complex Phenotypes, Shanghai Engineering Research Center of Industrial Microorganisms, School of …. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Science and Technology Commission, Shanghai Pudong Science and Technology Devolopment Fund.
Abstract (Originalsprache)
Background
Idiopathic pulmonary fibrosis (IPF) is closely associated with fibroblast proliferation, macrophage polarization, and the accumulation of extracellular matrix (ECM). Targeting CSF-1R can rebalance macrophages, reduce ECM deposition, and block pro-fibrotic signaling.
Methods
A Fab fragment targeting CSF-1R was screened via phage display. After sequence optimization, it was constructed into an IgG1 antibody (BC006). In vitro activity, domain binding, and signaling blockade were investigated, and in vitro safety indicators were evaluated. Efficacy was assessed using an induced IPF organoid-on-a-chip and bleomycin-induced mouse model. In vivo safety evaluation was conducted in cynomolgus monkeys.
Results
BC006 showed an EC50 value of 226 ± 57 nM and a KD of 30 ± 2 nM. It specifically bound to the Ig4-5 domain of CSF-1R by inhibiting receptor dimerization without blocking ligand binding. It could dose-dependently inhibit the differentiation of monocytes into M2 macrophages and exert anti-IPF effects. In the induced IPF organoid-on-a-chip model, BC006 maintained lung barrier function and decreased α-SMA and Collagen I. It also improved lung function and attenuated the degree of fibrosis in the mouse model. Moreover, BC006 had no ADCC, CDC, cytokine release, or hemagglutination, and demonstrated favorable safety profiles in cynomolgus monkeys.
Conclusions
BC006 is a novel anti-fibrosis antibody specifically targeting the CSF-1R Ig4-5 domain and offers a new therapeutic strategy for IPF.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Genetics and Development of Complex Phenotypes, Shanghai Engineering Research Center of Industrial Microorganisms, School of Life Sciences, Fudan University, Shanghai 200438, China.
- Dragon Boat Biopharmaceutical Co., Ltd., Shanghai 201203, China.
ORCID-Profile: Wusong Luo, Tao Wang, Kenghoe Lok, Yao Li
Förderung
- Shanghai Science and Technology Commission
- Shanghai Pudong Science and Technology Devolopment Fund
Zitieren
APA
Luo, W., Shao, Z., Wang, T., Lok, K., Zhang, R., & Li, Y. (2026). A CSF-1R Ig4-5 Domain-Targeting Antibody for the Treatment of Idiopathic Pulmonary Fibrosis. Antibodies, 15(4), 76. https://doi.org/10.3390/antib15040076
Vancouver
Luo W, Shao Z, Wang T, Lok K, Zhang R, Li Y. A CSF-1R Ig4-5 Domain-Targeting Antibody for the Treatment of Idiopathic Pulmonary Fibrosis. Antibodies. 2026;15(4):76. doi:10.3390/antib15040076
BibTeX
@article{Luo2026,
author = {Luo, Wusong and Shao, Zhe and Wang, Tao and Lok, Kenghoe and Zhang, Rongjing and Li, Yao},
title = {A CSF-1R Ig4-5 Domain-Targeting Antibody for the Treatment of Idiopathic Pulmonary Fibrosis},
journal = {Antibodies},
year = {2026},
volume = {15},
number = {4},
pages = {76},
doi = {10.3390/antib15040076}
}
EUVIMED